- Poster presentation
- Open Access
Rituximab is a therapeutical option for juvenile microscopic polyangiitis
Pediatric Rheumatology volume 6, Article number: P268 (2008)
Microscopic polyangitiis is characterized by anti-neutrophil cytoplasmic antibodies (ANCA) and small vessel vasculitis. The diseases usually respond to cyclophosphamide (Cyc) but some patients are therapy resistant. Rituximab (RIT) is a chimeric antibody to CD20 causing lysis of B-lymphocytes and used for treatment of lymphomas. RIT has also been successfully used in patients with rheumatoid arthritis (RA), idiopathic thromobocytopaenic purpura, autoimmune haemolytic anaemia, cold agglutinin disease, systemic lupus erythematosus and vasculitides.
A 16-year old female patient with hemoptysis, nephritis, dermatitis was diagnosed as a myeloperoxidase-ANCApositive microscopic polyangiitis. The patient was resistant to conventional therapy or had relapsed repeatedly after cessation of cyclophosphamide (Cyc). The patient was treated with intravenous infusions of rituximab (RIT).
RIT seems promising and safe in pediatric microscopic polyangiitis. Controlled studies should be conducted.
About this article
Cite this article
Brunner, J., Freund, M., Prelog, M. et al. Rituximab is a therapeutical option for juvenile microscopic polyangiitis. Pediatr Rheumatol 6, P268 (2008) doi:10.1186/1546-0096-6-S1-P268
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus